Profiling the gut and oral microbiota of hormone receptor-positive, HER2-negative metastatic breast cancer patients receiving pembrolizumab and eribulin.

Microbiome Res Rep · 2025 · PMC11977384 · PMID 40207279

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

Visualization showed an increasing trend in the relative abundance of B. fragilis in the CB patients compared to the no-CB group [ Figure 4C ], with a statistically significance difference observed at EoT ( P = 0.0009).

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.